Weekly Analysts’ Ratings Changes for BioLife Solutions (BLFS)

BioLife Solutions (NASDAQ: BLFS) recently received a number of ratings updates from brokerages and research firms:

• 7/28/2026 – BioLife Solutions was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/27/2026 – BioLife Solutions had its “equal weight” rating reaffirmed by Stephens. They now have a $31.00 price target on the stock, down from $32.00.
• 7/27/2026 – BioLife Solutions was downgraded by Stephens from “overweight” to “equal weight”. They now have a $31.00 price target on the stock, down from $32.00.
• 7/25/2026 – BioLife Solutions was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/23/2026 – BioLife Solutions was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $31.00 price target on the stock, up from $30.00.
• 7/23/2026 – BioLife Solutions was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $31.00 price target on the stock, down from $32.00.
• 7/23/2026 – BioLife Solutions was given a new $31.00 price target by William Blair.
• 7/22/2026 – BioLife Solutions was downgraded by TD Cowen from “buy” to “hold”. They now have a $31.00 price target on the stock, down from $33.00.
• 7/22/2026 – BioLife Solutions was downgraded by Craig Hallum from “buy” to “hold”. They now have a $31.00 price target on the stock.
• 7/22/2026 – BioLife Solutions was downgraded by Lake Street Capital from “buy” to “hold”. They now have a $31.00 price target on the stock, down from $33.00.
• 7/22/2026 – BioLife Solutions was downgraded by Maxim Group from “strong-buy” to “hold”.
• 7/17/2026 – BioLife Solutions had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity

In other news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the completion of the transaction, the insider owned 4,757,165 shares of the company’s stock, valued at approximately $112,744,810.50. This represents a 12.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 1,200,000 shares of company stock worth $28,125,000. Insiders own 2.20% of the company’s stock.

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.